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 ABSTRACT 
Background: SOX2 and SOX9 are commonly overexpressed in glioblastoma, and regulate 
the activity of glioma stem cells (GSCs). Their specific and overlapping roles in GSCs and 
glioma treatment remains unclear.  
Methods: SOX2 and SOX9 levels were examined in human biopsies Gain and loss of 
function determined the impact of altering SOX2 and SOX9 on cell proliferation, senescence, 
stem cell activity, tumorigenesis and chemoresistance.  
Results: SOX2 and SOX9 expression correlates positively in glioma cells and glioblastoma 
biopsies. High levels of SOX2 bypass cellular senescence and promote resistance to 
temozolomide. Mechanistic investigations revealed that SOX2 acts upstream of SOX9. 
mTOR genetic and pharmacologic (rapamycin) inhibition decreased SOX2 and SOX9 
expression, and reversed chemoresistance.  
Conclusions: Our findings reveal SOX2-SOX9 as an oncogenic axis that regulates stem cell 
properties and chemoresistance. We identify that rapamycin abrogate SOX protein expression 
and provide evidence that a combination of rapamycin and temozolomide inhibits tumor 
growth in cells with high SOX2/SOX9.  
 
Expert opinion: SOX2 and SOX9 have the potential to become biomarkers for the 
identification of GSCs and poor patient outcome in the clinic. Their expression might be used 
for patient stratification. We postulate the combination of rapamycin to conventional therapy 
in glioblastoma patients whose biopsies express elevated SOX2/SOX9. 
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 1. INTRODUCTION 
Glioblastoma multiforme is the most common and malignant adult primary brain tumor with 
an incidence ranging from 2 to 10 cases per 100,000 people per year. The incorporation of 
Temozolomide (TMZ) to clinical practice resulted in improved quality of life, delayed tumor 
progression, and extended patient survival [1]. Current standard treatment includes 
multimodal therapy of surgery followed by concomitant radiotherapy and TMZ. However, 
most patients develop refractory disease and tumor recurrence because of the intrinsic or 
acquired chemoresistance of glioma cells. There are several characteristics of glioblastoma 
that are responsible for difficulties of current therapies, including: genetic, molecular and 
morphological heterogeneity [2, 3], the presence of a subpopulation of cancer cells (called 
Glioma Stem Cells, GSCs) that drives tumor formation and maintenance [4]; and the 
resistance of GSCs to therapeutic treatments [5, 6]. Therefore, it is critical to elucidate the 
molecular mechanisms underlying the chemoresistance of glioma cells to discover more 
efficient therapeutic treatments.  
 
GSCs share phenotypic and functional characteristics with neural stem cells (NSCs), such as 
self-renewal and multipotency. Accumulating evidence indicates that dysregulation of genes 
and pathways controlling normal NSCs play a role in the regulation of GSCs. SOX (Sex-
determining region Y (SRY)-box) are a family of transcription factors characterized by a 
conserved high mobility group (HMG) DNA-binding domain. They control several 
developmental processes and are involved in the maintenance of stem cell activity in a wide 
range of tissues during embryogenesis and adult stages [7]. Their functions are particularly 
relevant in the central nervous system (CNS). Moreover, mutation and dysfunction of SOX 
factors are implicated in a broad variety of cancers, including glioblastoma [8].  
 
 SOX2 is necessary at early stages of neurodevelopment, it is highly expressed in the areas 
where NSCs are present during embryogenesis and in the adult stages and its genetic 
inactivation leads to NSCs differentiation [9, 10]. It is also one of the factors necessary for 
pluripotent and neural stem cell reprogramming [11-13]. In regards to glioblastoma, SOX2 is 
highly expressed in clinical samples [2], [14-16], and these high levels identify a subset of 
patients with poor clinical outcome [17]. SOX2 activity is required to sustain stem cell 
identity with its knockdown significantly impairing GSCs self-renewal and ability to form 
tumors in vivo [18, 19]. SOX2 is also one of the master transcription factors responsible for 
the reprograming of differentiated glioblastoma cells into induced GSCs [20], together 
establishing a major functional relevance of SOX2 in the maintenance of GSCs and 
glioblastoma progression. However, its function in response to therapy remains poorly 
understood. 
 
SOX9 belongs to the related SOXE subgroup, whose expression is also associated with NSCs 
[21]. It is essential for directing cells to late NSC stages when gliogenesis is prominent [22]. 
The activity of SOX9 has also been associated to brain primary tumors. Thus, SOX9 levels 
are more elevated in glioma than in healthy brain tissue and increasing expression correlates 
with higher WHO grade gliomas [23]. In glioblastoma, strong SOX9 staining is associated 
with lower Karnofsky score, lower disease-free and overall patient survival rates [24, 25]. 
Functionally, ectopic expression of SOX9 cooperates to transform NSCs and form tumors 
[26].  
Different studies have shown an association between SOX2 and SOX9 expression within the 
developing CNS neurogenic areas in the retina, spinal cord and dorsal telencephalon [21, 27]. 
Similar effects have shown in adult stem cells in the subventricular zone and cerebellum [21, 
 28, 29]. However it is unknown whether these two SOX factors cooperate in GSCs self-
renewal and/or in glioblastoma chemoresistance. 
  
 2. PATIENTS AND METHODS 
2.1. Patients and tumor samples  
The Basque Biobank for Research O+EHUN provided the human glioblastoma samples. The 
study included biopsies from 27 patients seen at Donostia University Hospital (San Sebastian, 
Spain), and diagnosed as primary glioblastoma grade IV according to the WHO criteria. The 
control group consisted of 3 healthy donors from the Basque Research Biobank for Research 
O+EHUN and mRNA was obtained from a mix of 6 adult brains (Ambion). All study 
participants signed informed consent form approved by the Institutional Ethical Committee. 
 
2.2. Cell lines and cultures   
Glioma cell lines U251MG (U251), U87MG (U87), A172 y U373 were purchased from the 
ATCC. The cell lines were cultured in DMEM (Gibco), supplemented with 10% FBS 
(Gibco), 100 U/ml penicillin and 100 µg/ml streptomycin for traditional monolayer cultures 
or in DMEM/F-12 supplemented with N2, B27 supplements (Fisher) and growth factors (20 
ng/ml basic fibroblast growth factor (bFGF), and 20 ng/ml epidermal growth factor (EGF)) 
(Sigma) for tumorspheres cultures. Cells were maintained at standard conditions of 37°C, 5% 
CO2 in humidified atmosphere. Glioblastoma primary tumors were dissociated and cells 
grown in tumorsphere medium for 10 days. Then, tumorspheres were mechanically and 
enzymatically disaggregated with accutase (Gibco), seeded for secondary neurospheres and 
injected in mice at early passage. Moreover, they were maintained in culture for at least 9 
passages. Differentiation assays were performed by removing bFGF and EGF and by adding 
1%FBS to the DMEM-F12 complete medium.  
 
For neurospheres assays, U87 and U251 were grown in GSCs medium for 10 days. Then, 
these spheres were disaggregated with accutase, and seeded for secondary neurospheres and 
 maintained in culture for another 10 days (2ry GSCs). For quantification studies 
500cells/well were seeded in non-treated 12-wells flat bottom plates and fresh media was 
added every 3 days to the plate. After 10 days tumorospheres were counted. For 2ry GSC 
assay, the same procedure was repeated. 
 
Lentiviral infections were performed as previously described [30]. For SOX2 or mTOR 
knockdown, cells were infected with pLKO.1 shSOX2 (a gift from Matthew Meyerson, 
Addgene plasmid 26353), shmTOR1 (a gift from David Sabatini, Addgene plasmid 1855) or 
empty vector. Infected cells were selected in the presence of 2 µg/ml puromycin and then 
maintained with 0.2 µg/ml puromycin (Sigma). For SOX9 knockdown, cells were transfected 
with a SOX9 shRNAs (Origene, sh1 or sh75) using Lipofectamine (Invitrogen) and selected 
in the presence of puromycin for 3 weeks. A non-specific shRNA (pRS) was used as a 
control. For stable overexpression of SOX2, lentiviral transductions were performed with a 
pLM-mCitrine-SOX2 construct (a gift from Ander Izeta, Biodonostia Institute) with pWXL-
GFP as control. Cells were infected at a MOI of 10 for 6 hour. SOX9 overexpression was 
achieved by transfection using Fugene with pCAGGS-SOX9. Temozolomide and rapamycine 
(Sigma) were dissolved in DMSO and cyclopamine in ethanol. 
 
2.3. Flow citometry 
For cell cycle assay, cells were fixed with ethanol and incubated with RNaseA and propidium 
iodide. Data were acquired in FACSCalibur flow cytometer (BD Biosciences) and processed 
using FACSDiva software. 
 
2.4. Senescence Associated β-galactosidase staining 
 To measure senescence, senescence-associated β-galactosidase (SA-β-gal) staining was 
performed using a commercial staining Kit (Cell Signaling), according the manufacturer’s 
guidelines.  
 
2.5. RNA analysis 
Total RNA was extracted with Trizol (Life Technologies). Reverse transcription was 
performed using random priming and Superscript Reverse Transcriptase (Life Technologies), 
according to the manufacturer’s guidelines. Quantitative real-time PCR was performed using 
Absolute SYBR Green mix (Thermo Scientific) in an ABI PRISM 7300 thermocycler 
(Applied Biosystems). Variations in input RNA were corrected by subtracting the number of 
PCR cycles obtained for GADPH.  
 
2.6. Western Blot analysis 
Immunoblots were performed following standard procedures. For SOX2 detection AB5603 
antibody (Millipore) was used, for SOX9 AB5535 antibody (Millipore) and for β-actin AC-
15 (Sigma). HRP-linked anti-rabbit or anti-mouse (SantaCruz Biotechnology) secondary 
antibodies, both at a 1:2000 dilution were used. Detection was performed by 
chemiluminescence using NOVEX ECL Chemi Substrate (ThermoFisher). 
 
2.7. Immunofluorescence  
Cells were fixed with 4% paraformaldehyde for 15 min, and washed with PBS supplemented 
with 0.3% Triton X-100 and 1% FBS, for 5 min at 4°C.  Subsequent to blocking for 1h with 
PBS and 1% FCS, cells were incubated with p-Histone3 (Abcam) or SOX9 (Millipore) 
antibodies for 2h. Nuclear DNA was stained with DAPI (Sigma). 
 
 2.8. Immunohistochemistry 
Tumors generated in mice were dissected, fixed in 10% formalin for 48h and embedded in 
paraffin. 4 micrometer-thick sections were stained with hematoxylin and eosin (H&E) using 
the Varistain Gemini ES machine (ThermoFisher). For immunohistochemistry, sections were 
rehydrated and heated in citrate buffer for 10 minutes for antigen retrieval. Endogenous 
peroxidase was blocked with 5% hydrogen peroxide in methanol for 15min. Anti-SOX2 
(Abcam), SOX9 (Millipore) and Ki67 (Abcam) primary antibodies were used. 
 
2.9. Cell viability MTT assay 
Cells were seeded in 96-well plates at a density of 2.5·103 cells per well and treated 24 hours 
later with the indicated concentrations of temozolomide, rapamycine and cyclopamine 
(Sigma) for 72 hours in sextuplicates. Then, cells were incubated with MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 0.25 mg/mL (Sigma) for 3 hours. 
Formazan produced by viable cells was dissolved in 150 µL of DMSO and absorbance 
determined at 570 nm in a microplate reader (Multiskan Ascent Thermo Electron 
Corporation). Results were presented as the percentage of viable cells relative to controls. 
 
2.10. In vivo carcinogenesis assays   
For subcutaneous injection, glioma cells were harvested with trypsin/EDTA and resuspended 
in PBS. 1x106 cells were injected subcutaneously into both flanks of Foxn1nu/Foxn1nu nude 
mice (8 weeks old).  Mice were observed on a daily basis and external calipers were used to 
measure tumor size at the indicated time points from which tumor volume was estimated. For 
therapy experiment, U251 were cultured for 48h with TMZ 0,1mM, rapamycin 1nM, the 
combination of both drugs or vehicle (control), previous bilateral implantation in nude mice. 
One week later, mice were injected intraperitoneally with TMZ (10mg/kg), rapamycin 
 (5mg/kg) and combination (10mg/kg and 5mg/kg respectively) twice per week for 12 weeks. 
Tumors were considered positive when palpable and the diameter was bigger than 3 mm. 
For xenotransplantation, GSCs were injected stereotactically into the frontal cortex of 6-8 
week-old NOD-SCID mice. Briefly, GSCs were disaggregated with accutase and 
resuspended in PBS. 1x105 cells were injected into the putamen using a stereotaxic apparatus. 
 
2.11. Data evaluation  
Data are presented as mean values ± S.E.M. with the number of experiments (n) in 
parenthesis.  Unless otherwise indicated, statistical significance (p-values) was calculated 
using the Student´s t -test.  Asterisks (*, **, and ***) indicate statistical significance (p < 
0.05, p < 0.01, and p < 0.001, respectively).  
  
 3. RESULTS 
3.1. SOX2 and SOX9 overexpression correlate in glioblastoma samples and GSCs 
We analyzed the expression of SOX2 and SOX9 in a cohort of human glioblastoma samples 
and compared them with healthy brain tissue. The expression of SOX2 and SOX9 was 
significantly up-regulated in glioblastoma. Indeed, 70% of the tumor biopsies showed 
overexpression (fold change higher than 1.5) of SOX2 (19 biopsies of 27), while 65% of them 
presented SOX9 up-regulation (18 of 27). Moreover, SOX2 was increased by an average of 
more than three-fold, while SOX9 was up-regulated by six-fold in tumors compared to brain 
tissue (Fig. 1A,B, Fig Suppl. 1). Interestingly, the correlation analysis showed a significant 
association between SOX2 and SOX9 expression (Fig 1B). In fact, 85% of the biopsies with 
SOX2 overexpression also presented increased levels of SOX9 (16 out of 19), whilst 75% of 
cases with moderate or low SOX2 (6 out of 8) presented low SOX9 as well (Fig 1B). Similar 
results were observed in the publically accessible data from The Cancer Genome Atlas 
(TCGA) (Fig suppl. 1). Together, these results demonstrate that high levels of SOX2 and 
SOX9 are associated in glioma biopsies. 
 
Next, we determined the association between SOX2 and SOX9 in freshly derived GSCs 
cultures from human patients. For this, cells dissociated from glioblastoma biopsies were 
plated in serum-free medium in the presence of EGF and bFGF growth factors. Two 
independent cultures (GB1, GB2) gave rise to long-term expanding cultures. These cultures 
were able to grow as tumorspheres, displayed multipotency and generated tumors when 
injected orthotopically in the brain of immunodeficient mice (Fig 1C and suppl. 2). 
Importantly, both SOX2 and SOX9, in addition to CD133 and OCT4, were highly expressed 
in these nondifferentiating conditions, and their levels were higher in GB1 cells, which 
generated tumors earlier (Fig 1D,E and suppl 2). When we checked their expression in 
 differentiation conditions, in the absence of growth factors and addition of 1% serum, both 
SOX2 and SOX9 decreased significantly (Fig 1D,E). These results extend the correlation of 
SOX2 and SOX9 to GSCs. 
 
Then, we studied their expression in a set of glioma cell lines. Western blotting and 
quantitative PCR revealed that the expression of SOX2 was very high in U251 and U373, 
while U87 and A172 expressed low levels (Fig 1G). Interestingly, the levels of SOX9 
correlated with SOX2 (Fig. 1G). Moreover, their levels in U251 cells are within the range of 
expression observed in GSCs and tumor biopsies (Fig. suppl 1, 2), suggesting that these high 
levels are of biological relevance. Cells with stem cells characteristics have been isolated in 
several glioma cells lines [31]. Therefore, we cultured U87 and U373 cell lines under NSC 
growth conditions. These cells grew as tumorspheres and produced tumors faster and larger 
than parental cells when injected in immunodeficient mice (Fig 1I,K and suppl 3). In this 
context, the levels of SOX2 and SOX9 were strikingly elevated in the tumors and in the 
cultures of tumorspheres compared to U87 and U373 parental cells (Fig 1H,J and suppl 3). 
This evidence further demonstrates the correlation between their expression and together 
reveal that the SOX2-SOX9 axis might define an oncogenic signaling that predict the 
presence of malignant GSCs.  
 
3.2. SOX2 regulated proliferation, senescence and self-renewal is mediated by SOX9 
To directly address the impact of SOX2 in the regulation of glioma cells and SOX9 
expression, we knocked-down SOX2 by using RNA interference in U251, cell line with the 
highest levels of SOX2 and SOX9. Western immunoblotting confirmed effective inhibition of 
SOX2 and revealed a marked reduction of SOX9 protein levels in shSOX2 cells (Fig. 2A, Fig 
suppl4), suggesting that SOX9 might act downstream of SOX2 in glioma cells. To further 
 characterize the regulation of SOX9 by SOX2, we measured SOX9 mRNA levels in cells 
with SOX2 knock-down, not detecting significant differences in relation to control cells (data 
not shown). Thus, the effect of SOX2 seems to be at translational instead of transcriptional 
level.  
 
To extend this finding, SOX9 was ectopically re-expressed in shSOX2 cells. Western blot 
assay showed that SOX9 restoration in U251 cells re-established the expression of SOX9 and 
increased the levels of SOX2 (Fig 2B), indicating that the efficiency of silencing was not 
complete (Fig suppl4). Moreover, we identified that ectopic SOX9 also increased the 
expression of SOX2 in control cells (Fig. 2B), together suggesting that a feedback loop might 
exist between SOX2 and SOX9. 
 
To determine whether SOX9 is necessary for SOX2 oncogenic activity, we next investigated 
the phenotypes associated to SOX2 silencing and whether SOX9 re-activation restored them , 
SOX2 knockdown led to a significant decrease of more than 2 fold in cell growth and number 
of p-Histone3 (P-H3) positive cells (Fig. 2C, suppl 4). Moreover, flow cytometry analysis 
showed increased number in G0/G1 and decreased in S phase of shSOX2 compared with 
control cells (Fig. 2D and suppl 4). This impairment in shSOX2 cell proliferation was 
accompanied by a significant increase in senescence measured by cytoplasmic β-
galactosidase activity and IL1α, interleukin associated to senescence-associated secretory 
phenotype [32] both elevated by more than 2.5-fold in cells with SOX2 silencing (Fig 2E,F, 
and suppl 4). Thus, impaired proliferation and increased senescence account for the reduction 
in cellular growth of SOX2 silenced cells. Moreover, SOX2 knockdown diminished sphere-
formation and self-renewal activities (Fig. 2G,H). Similar results were obtained in limiting 
dilution analysis (Fig. suppl 4), further providing evidence for a decrease in self-renewal 
 activity in the absence of SOX2 [19]. When SOX9 was ectopically re-expressed in shSOX2 
cells, cell proliferation was significantly increased (Fig. 2I), senescence associated β-
galactosidase activity significantly decreased (Fig. 2J and suppl 5) and the ability to form 
colonies at low density and spheres increased in SOX9 restored cells (Fig. 2K and suppl 5). 
However, SOX9 reactivation did not restore completely the numbers observed in control cells 
(data not shown) indicating that the oncogenic activity of SOX2 is, at least in part, mediated 
by SOX9.  
 
In order to further characterize the significance of this axis in glioma cells, we knocked-down 
SOX9 activity in U251 cells. shSOX9 (sh1) transduced cells presented significantly lower 
number of p-Histone3 positive cells (Fig·3A,B, and suppl 6) and generated lower number of 
foci in soft-agar and formed tumors later than control cells (Fig3C and suppl 6). Together, 
our results demonstrate that genetic silencing of SOX2 and SOX9 suppresses proliferation 
and tumorigenicity of glioma cells and indicate that their inhibition might be a novel 
therapeutic strategy for glioblastoma. 
 
3.3. Overexpression of SOX2 and SOX9 promotes proliferation and stem cell activity  
Next, we introduced ectopic SOX2 in U87 cells with the lowest levels of endogenous SOX2 
and SOX9. We confirmed the overexpression of SOX2, and interestingly, SOX9 levels were 
also elevated (Fig. 3D, Fig Suppl7). Together with the above data, these results strongly 
indicate that SOX2 modulates the activity of SOX9 expression. We also measured SOX9 
mRNA levels in cells with SOX2 overexpression without detecting significant differences 
compared to control cells (data not shown). Phenotipically, cells with increased SOX2 
expression exhibited higher cell growth curves and rates of proliferation compared to control 
cells, (Fig. 3E,F). Moreover, we assessed the effect of SOX2 on self-renewal and found that 
 SOX2 overexpression led to an increase in the generation of tumorspheres. While control 
cells formed an average of 5 spheres, SOX2 overexpressing cells generated and average of 
over 20 spheres (Fig. 3G). Similarly, transient overexpression of SOX9 was sufficient to 
increase the number of U87 derived spheres (Fig. 3H,I) and induced the formation of larger 
tumors (Fig. 3J). Collectively, our data revealed that SOX2 and SOX9, acting in the same 
axis, are not only necessary for the maintenance but their elevated activity also facilitates 
self-renewal activity and tumor growth in glioma cells. 
 
3.4. SOX2 expression modulates TMZ sensitivity  
The evidence of GSCs as responsible for resistance to therapeutic treatments [33] together 
with our data of SOX2/SOX9 expression associated to malignant GSCs, prompted us to 
hypothesized that their high levels could be involved in cellular resistance to TMZ. To test 
this idea, we first analysed SOX2 and SOX9 expression in U251 and U87 cells cultured with 
increasing concentrations of TMZ for 24 hours. We found that both SOXs were elevated in 
response to 100 and 200µM of TMZ, more markedly with the highest concentration (Fig. 
4A), suggesting that this axis may be involved in the underlying resistance to current 
chemotherapy. To further determine this hypothesis, cell lines with high and low 
SOX2/SOX9 were exposed to different concentrations of TMZ for 72 hours and cell 
chemosensitivity was measured by MTT assay. U251 and U373 cells, with high levels of 
both SOX factors, were more resistant (% of toxicity lower than 15% in both lines) than 
A172 and U87 cells (% of toxicity between 30 and 50%) (Fig. 4B) Together, these findings 
confirm that high levels of SOX2 and SOX9 correlate with temozolomide resistance. 
 
Next, we characterized the role of SOX2 in response to TMZ performing additional MTTs 
assays. SOX2 overexpression significantly increased the resistance of U87 cells, as observed 
 by the enhancement of cell growth to increasing concentrations of TMZ (Fig. 4C), whilst 
SOX2 knockdown increased the chemosensitivity of U251 glioma cells to TMZ (Fig. 4D). To 
identify whether SOX9 regulated SOX2 response to TMZ, we repeated the MTT experiment 
with U251 shSOX2 cells with or without SOX9 restoration. Interestingly, shSOX2 with SOX9 
exhibited a growth advantage in the presence of different doses of TMZ compared to shSOX2 
(Fig. 4E). The above-mentioned data indicate that SOX2 activity modulates the sensitivity of 
glioma cells to TMZ by regulating SOX9 expression and suggest that pharmacological 
inhibition of SOX2 might be a novel strategy to overcome TMZ resistance in a subset of 
glioblastoma with high levels of SOX2-SOX9. 
 
3.5. Rapamycin treatment decreases SOX2 expression and TMZ resistance 
In an effort to identify agents that could silence the expression of SOX2 in glioma cells, we 
tested the effect of rapamycin, an inhibitor of the mTOR complex 1, which is known to affect 
viability and proliferation of glioma cells, and has been shown to inhibit the expression of 
SOX2 for cell reprogramming [34, 35]. First, we cultured several cell lines with 10nM of 
rapamycin noting that the expression of SOX2 was markedly reduced at protein and mRNA 
levels specifically in U251 and U373 cells with endogenous high levels of SOX2 (Fig. 5A,B, 
Fig suppl 7). Similar effect was detected in SOX9 expression, extending the action of this 
agent on SOX proteins from healthy to cancer cells. The inhibitory effect of rapamycin was 
concentration dependent (from 1 to 100nM) and in time dependent manner (24-48h) (Fig. 
5A,B Fig suppl 7). The reduction in SOX9 levels was more intense (between 60 and 80%) 
than in SOX2 (30 to 60%), suggesting that rapamycin-induced SOX9 inhibition is not 
exclusively directed through SOX2. The above concentration response curves further reveal 
that rapamycin exerted a negative effect in SOX expression even at concentration 10 times 
below (1nM) the ones usually employed in cell culture. We therefore evaluated whether the 
 effect on SOX2 and SOX9 expression was directly mediated by mTOR signaling inhibition, 
and knocked-down mTOR expression in U251 cells. 72 hours after antibiotic selection, we 
observed a severe decrease in mTOR mRNA levels and a striking decline in phosphorylation 
of AKT and S6, well established mTOR effectors (Fig. 5C,D), demonstrating the efficient 
silencing of mTOR machinery in our U251 glioma model (Fig. 5D). In this context, SOX2 
and SOX9 protein levels were also reduced identifying that SOX2 and SOX9 are downstream 
targets of mTOR pathway as shown by genetic and pharmacological studies. 
 
To confirm the role of mTOR signaling in glioma cell activity, we further characterized the 
effect of mTOR silencing in functional studies. Interestingly, cell growth and the number of 
spheres were dramatically diminished (Fig. 5E,F) further confirming the impact of mTOR in 
self-renewal and GSC maintenance [36]. Moreover, these studies reveal that genetic inhibion 
of mTOR and SOX proteins display the same cellular phenotype further extending the 
association between them. In summary, our results show that SOX2/SOX9 expression can be 
silenced with the pharmacological inhibition of mTOR machinery. Similar results were 
obtained with cyclopamine, inhibitor of the SonicHedhog molecular pathway (Fig. suppl 8), 
together demonstrating that pharmacological silencing of SOX2 and SOX9 activity is 
plausible with current agents. 
 
Combined therapeutic approaches acting synergistically have been proven more effective 
than individual treatments. We therefore tested whether rapamycin (or cyclopamine) could 
represent a potential enhancer of the cytotoxic effects of TMZ and sensitizes cells with 
elevated levels of SOX2. Accordingly, we performed MTT assays in which U87 and U251 
cells were treated with a constant dose of 100µM TMZ together with 1 and 10nM of 
rapamycin or 5 and 10μM of cyclopamine (concentrations that significantly inhibited SOX2 
 expression). First, we detected that the citotoxic effect of 5 and 10μM of cyclopamine in 
U251 cells was higher (18 and 24%) than U87 (14 and 19%), athough we did not observe an 
additive effect of the combination of TMZ and cyclopamine treatment compared to single 
treatment (Fig. suppl 8). On the other hand, combined treatment of rapamycin and TMZ 
achieved a stronger citotoxic effect than with single agents alone (Fig. 5G). Moreover the 
concomitant treatment of rapamycin and TMZ exerted a greater tumor suppressive effect in 
SOX2-SOX9 high expressing than in low expressing cells (Fig. 5G). Indeed, the percentage 
of toxicity in U251 cells was 55 and 57% in TMZ plus rapamycin 1 and 10nM, respectively, 
compared to 43 and 46% in U87 cells. Of note, the synergestic action of rapamycin and TMZ 
was achieved even at the low concentration of 1nM and was of similar degree than 10nM. To 
determine whether this effect was mediated by SOX2 and SOX9, we measured their 
expression in cells cultured with TMZ (100µM), rapamicin (1nM) or the combination of them 
for 48hours. Remarkably, SOX2 and SOX9 were much lower in rapamycin or in combination 
than in non treated or TMZ alone cells (Fig 5H). These results indicate a sensitization of 
TMZ-resistant cells by rapamycin likely through SOX2 and SOX9 downregulation.  
 
To corroborate the synergistic effect of TMZ and rapamycin in cells with elevated SOX2 and 
SOX9 expression, we studied their efficacy in tumor formation in vivo. Thus, we injected 
U251 cells in athymic inmunodeficient mice subcutaneously and since one week later, mice 
received intraperitoneally TMZ (10mg/kg), rapamycin (5mg/kg) and combination (10mg/kg 
and 5mg/kg respectively) twice per week. In the case of untreated animals, tumors started to 
be detected 30-40 days after injection and 100% mice developed them after 2 months. In 
contrast, treatment with rapamycin or TMZ delayed the formation of the tumors, with around 
50% of them presenting tumors 2 months after injection. Remarkably, these numbers were 
lower in the combined treatment group with only 25% of mice with tumors (Fig 5I). 
 Together, these data demonstrate that combining rapamycin with TMZ enhances the efficacy 
of TMZ against glioma cells, particularly in the subset with high levels of SOX2 and SOX9.  
  
 4. DISCUSSION 
Different studies by us and others have shown that expression of SOX2 is often increased in 
glioblastoma and that this up-regulation is due to genetic amplification and epigenetic 
mechanisms [2], [14-16]. Notably, beyond high expression of SOX2 in GBM biopsies, the 
genetic inhibition of SOX2 expression decreases tumor cell proliferation, causes depletion of 
self-renewal and subsequently tumor regression [18, 19]. In this study, we have identified that 
SOX2 inhibition induces cellular senescence in differentitated U251 cells. Moreover, the 
increased levels of IL1α observed in shSOX2 U251 cells suggest that SOX2 might be 
involved in paracrine senescence [32]. Gangemi and collaborators did not observe an increase 
in senescence associated β-galactosidase activity when SOX2 was silenced in human derived 
GSCs [19] indicating that SOX2 might exert different actions within the cellular 
heterogeneity of the tumor bulk. These results suggest that inactivation of SOX2 in GSCs 
induces differentiation whilst in differentiated ones facilitates senescence or apoptosis. 
Morever, we show that overexpression of SOX2, in addition to promote other relevant 
phenotypic properties such as invasiveness and migration [16], it is a necessary condition for 
maintaining GSCs and therefore essential for GBM propagation. Further supporting this 
notion, SOX2 belongs to the core set of transcription factors (with POU3F2, SALL2, and 
OLIG2), which are sufficient to reprogram differentiated cells into GSCs [20]. Altogether 
these data confirm that tumor cells harboring high levels of SOX2 protein are addicted to it 
and have a dependence on this factor to survive.  
 
In this work, we have identified that SOX2 and SOX9 expression correlate in glioma cells 
and that the oncogenic activity of SOX2 is at least partially mediated by the latter. In support 
of these actions, it has been previously shown that SOX9 plays a key role in the regulation of 
cellular proliferation, senescence and self-renewal [26, 37, 38]. Moreover, we show that this 
 regulation occurs at post-transcriptional levels and that there is a feed back loop between 
them. A recent study observed that Sox2 regulates Sox9 protein at the level of mRNA 
translation in oligodendrocytes, identifying miR-145 as a candidate mediator in this process 
[39]. It is possible to surmise that the same pathway is acting in glioma cells. Indeed, it has 
been shown that SOX2 inactivation induces the expression of miR-145 [40], while this 
miRNA regulates and inhibits SOX9 to function as a tumor suppressor [25]. Our results also 
highlight that SOX transcription factors act sequentially in the regulation of GSCs, 
mimicking the action of those in neural lineage development [18, 41], and indicate that SOX2 
is a master regulator of GSCs, which together with SOX9 might form a relevant molecular 
node that sustains tumor maintenance and progression.  
 
Temozolomide (TMZ) is currently the most efficient chemotherapy for GBM. Indeed, its 
addition extended patient median survival from approximately 12 to 15 months [42]. Damage 
generated by TMZ can be repaired by MGMT, thus inducing treatment resistance, while 
methylation of the MGMT promoter leads to an increase in TMZ sensitivity. Our results 
show that cells with high levels of SOX2 are more resistant to TMZ and silencing it sensitizes 
against this chemotherapeutic agent in vitro and in vivo. Of note, the cell lines used in our 
experiments exhibit MGMT promoter hypermethylation status. Given that SOX2 is included 
in the proneural subset in different glioblastoma classifications [43, 44] group which has been 
demonstrated to be resistant to the conventional therapeutic regimen of radiotherapy and 
temozolomide, SOX2 might be postulated as one of the key responsible for resistance to 
current chemotherapy in glioblastoma. Therefore, targeting the activity of SOX2 may offer a 
new promising therapeutic treatment modality.  
 
 In an effort to identify drugs or molecules that might inhibit efficiently the expression of 
SOX2 (direct or indirectly), we found that inhibitors of the SHH signaling cascade 
(cyclopamine) and mTOR (rapamycin) reduced significantly, between 40 and 80%, the 
activity of SOX2 and SOX9, demonstrating that the pharmacological silencing of SOX2 is 
feasible using inhibitors of these signaling pathways. It is important to note that SHH and 
particularly PI3 kinase/mTOR pathway is aberrantly active in a high percentage of GBMs 
[14]. Our results indicate that their action might be modulated through SOX2 and SOX9. 
Consistent with the strategy to silence SOX2 activity in glioma, down-regulation of SOX2 
conferred sensitivity to treatment with PDGF and IGF1 receptor inhibitors [44] and 
vaccination with Sox2 peptides elicited a response that significantly delayed tumor 
development in mice [45], underscoring the feasibility of using SOX2 as a target in different 
therapeutic approaches.  Furthermore, it has been shown that elevated expression of SOX2 
protein desensitizes tumor cells to current therapies present in the clinic such as hormone 
therapy in breast cancer [46] and chemotherapy in medulloblastoma [47].  
 
A growing number of evidence indicates that combining drugs with chemotherapeutic agents 
is becoming a more effective therapeutic option in cancer. Our results identified that the 
concomitant treatment of rapamycin and TMZ exerted a higher cytotoxic effect in vitro and 
in vivo in cells expressing endogenous high levels of SOX2-SOX9, suggesting that the 
addition of rapamycin to TMZ treatment could potentially enhance the efficacy of this 
therapy against human glioblastoma, particularly in the subset of patients whose biopsies 
express elevated levels SOX2 and SOX9.  
 
Clinically, we have observed that there is a strong correlation between SOX2 and SOX9 
expression in patient biopsies. Independent studies demonstrated that elevated levels of 
 SOX2 and SOX9 are associated with a subgroup of patients with lower median survival and 
also that they are part of a signature of stem cell markers related with worse prognosis in 
glioblastoma [17, 24]. Our results together with this evidence demonstrate that the assessment 
of the activity of SOX2-SOX9 might be a useful prognostic and predictive marker in 
glioblastoma. Moreover, our results postulate the incorporation of the expression of SOX 
factors to patient stratification and the concept of personalized medicine, providing a 
rationale for the combination of rapamycin with TMZ in glioblastoma, particularly in the 
subset of patients with high levels of SOX2 and SOX9.  
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 8. FIGURE LEGENDS   
 
Figure 1. SOX2 and SOX9 are co-expressed in human glioblastoma samples, GSC and 
glioma cell lines 
(A) SOX2 and SOX9 mRNA levels were assayed in a set of healthy brain tissue as control 
(n=9) and GBM (n=27) samples. q-PCR data are normalized to GAPDH expression and 
expression in tumors is relative to healthy brain tissue (B) Analysis of the correlation of 
SOX2 and SOX9 expression in human glioblastoma samples (Fisher exact Test =0.006; 
Spearman correlation =0.02). (C) Kaplan-Meier curve representing the survival of NOD-
SCID mice that were xenotransplantated with GB cell lines (n=5) (D) Representative image 
of higher levels of SOX2 and SOX9 in GB1 and GB2 cells grown in stem cell medium 
compared to differentiation conditions (n=3). (E) mRNA expression of the indicated GSC 
markers were analyzed in GB2 and GB2 cells (n=3). (F) Representative immunoblots of 
SOX2 and SOX9 expression in different glioma cell lines (n=5). (G) SOX2 and SOX9 
expression levels in U87 and U373 grown in serum (parental cells) or in stem cells medium 
(2ry GSC) (n=5). (H) U87 and U373 parental cells and those grown as tumorspheres were 
injected subcutaneously in nude mice (n=8 for condition) and growth of the tumors was 
scored at the indicated time points. (I) Representative images of Ki67, SOX2 and SOX9 
immunohistochemical staining in U373 derived tumors (n=4). (J) Comparative of the size of 
the tumors generated by U373 parental and 2ry GSCs. Statistical significance was obtained 
with Student’s T test (P ≤ 0.05*; P ≤ 0.01**; P ≤ 0.001***). 
 
Figure 2. Downregulation of SOX2 leads to decreased proliferation and self-renewal in 
U251 cells via SOX9. 
U251 cells were infected with a shSOX2 or shSOX9 and cells examined for protein 
expression and functional assays (at least n=4). (A) Representative Immunoblots of SOX2 
 and SOX9 derived from two different and independent lentiviral infections with a shSOX2 
construct (n=4). (B) Representative western blot of SOX2 and SOX9 in U251 cells 
transduced with the indicated conditions (n=3). (C) shSOX2 impairs proliferation as shown 
by the quantification and representative image of P-H3 positive cells (n=4). (D)Cell number 
in each cell cycle phase in empty vector and shSOX2 condition (n=2). (E)Quantification of 
senescence associated β-galactosidase positive cells in shSOX2 and control cells (n=4). 
(F)Expression of IL1α mRNA levels in shSOX2 cells. qRT-PCR data are normalized to 
GAPDH expression and are expressed relative to the pLKO control condition (n=3). 
(G)Quantification of spheres (1ry) forming capacity in shSOX2 cells after 10 days in culture. 
The numbers are relative to empty vector transduced cells (n=4). HNumber of 2ry spheres 
generated in both control and shSOX2 conditions after 8 days in culture, and relativized to the 
control (n=3). (I) Numbers of P-H3 positive cells were quantified in shSOX2 and 
shSOX2+SOX9 transduced U251 cells (n=3). (J) SOX9 restoration decreases senescence 
associated β-galactosidase activity in U251 cells (n=4). (K) Quantification of tumorspheres 
forming capacity in shSOX2+SOX9 cells after 7 days in culture. The numbers are relative to 
U251 shSOX2 cells (n=4).  
 
Figure 3. Effect of SOX2 and SOX9 gain of function in glioma cells 
 (A) Representative image of SOX9 levels in pRS or shSOX9 (sh1) cells (B) Quantification of 
P-H3 positive cells in pRS or sh1 cells. (C) Kaplan-Meier curve representing the survival of 
NOD-SCID mice that were xenotransplantated with pRS control or sh1 cells (n=4). (D) 
Representative western blot of SOX2 and SOX9 in U87 cells lentivirally transduced with 
pLM-mCitrine-SOX2 or control construct (n=3).  (E) Cell growth assay comparing control 
and SOX2 overexpressing U87 cells.  (n=5). (F) Number of P-H3 positive cells detected in 
the indicated U87 cells. (n=5). (G) Quantification of tumorsphere formation capacity of cells 
 with ectopic SOX2 compared to control cells (n=4). (H) Representative western blot of 
SOX9 levels in U87 cells tranfected with pCAGGS SOX9 or empty vector (control). (I) 
Quantification of spheres generated in SOX9 and control U87 cells (n=4). (J) Control and 
SOX9 U87 cells were injected subcutaneously (s.c) in nude mice (n=6) and growth of the 
tumors was scored at the indicated time points.  
 
Figure 4. Effect of TMZ treatment in glioma cells with different activity of SOX2 and 
SOX9. 
(A) SOX2 and SOX9 expression levels in U87 and U251 cells cultured with increasing doses 
(100 and 200uM) of TMZ (n=3). Data are relative to DMSO treated condition. (B) MTT 
assay of different glioma cell lines in the presence of increasing doses of TMZ for 72h (n=6). 
Values are relative to control cells treated with DMSO. (C) pLM-mCitrine-SOX2 U87 
infected cells were cultured with the indicated doses of TMZ for 72h (n=3). Cell viability was 
expressed as the percentage of MTT reduction, assigning the 100% value to the absorbance 
of the control cells. (D) shSOX2 transduced U251 cells were treated with the indicated doses 
of TMZ and cell viability measured 72h later (n=5). (E) Cell viability in shSOX2 and 
shSOX2+SOX9 U251 cells (n=3). Statistical significance was obtained with Student’s T test 
(P ≤ 0.05*; P ≤ 0.01**; P ≤ 0.001***). 
 
Figure 5. mTOR signaling inhibition reduces SOX2 and SOX9 and cooperates with 
TMZ 
(A) Representative western blot of the effect of 10 and 100nM doses of rapamycin in SOX2 
and SOX9 in U251 cells. (B) Dose (1, 10 and 100nM) and time (24,48h) dependent effect of 
rapamycin in SOX2 and SOX9 mRNA levels in U251 cells. (C) mTOR mRNA in U251 cells 
lentivirally transduced with pLKO or mTOR shRNA (shTOR) (n=2). (D) Representative 
 image of SOX2, SOX9, P-S6K and P-Akt in the indicated U251 genotypes. (E) Cell growth 
assay comparing control and shTOR (n=2). (F) Sphere formation capacity in shTOR and 
control cells (n=2) (G)  MTT assay of U87 and U251 cells cultured with TMZ (100µM), 
rapamycin (1-10nM) and combination of both for 72h (n=3). (H) Kaplan meier curve 
showing generation of tumors from subcutaneously injected U251 cells after 12 weeks of 
treatment with TMZ (10mg/Kg) (n=8), rapamycin (5mg/Kg) (n=8) and combination of both 
(10mg/Kg and 5mg/Kg respectively) (n=12). Non-treated (n=8) mice were used as control. 
LogRank Test is 0.0323 for TMZ, 0.040 for rapamycin and 0.0003 for the combination of 
both compared to non treated 
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Supplementary Figures 
Figure 1. Characterization of SOX2 and SOX9 levels in GBM 
(A) Expression of SOX2 and SOX9 mRNA in each of the 27 human glioblastoma samples. 
Healthy brain tissue as control is included in a circle. (B) Determination of SOX2 and SOX9 in 
11 human glioblastoma samples (GBM-GBM11), two independent healthy tissues (HT) and 
U251 and U87 cell lines. (C) Expression of SOX2 and SOX9 in human glioblastoma samples 
included in the TCGA (The Cancer Genome Atlas) studies. 
Figure 2. Characterization of SOX2 and SOX9 levels in GB1 and GB2 cells 
(A) Representative image of Hematoxilin/Eosin and SOX9 staining in GB1 and GB2 derived 
tumors. (B) Comparison of SOX2 and SOX9 levels in conventional glioma cell lines and GSCs. 
Indicated values are the average of 2 independent experiments and are normalized to their 
expression in U87. (C) SOX2, SOX9, CD133 and OCT4 expression were assayed in GB1 and 
GB2 grown as spheres or in differentiation media.  
Figure 3. SOX expression in U87 and U373 GSCs. 
(A) SOX2, SOX9, CD133 and OCT4 mRNA levels were assayed in U87 and U373 cells and 
compared to their respective 2ry GSC population. (B) Quantification for SOX2 and SOX9 in 
U87MG and U373MG cells and their respective 2ryCSC (N=5). (C) Representative image of 
subcutaneously generated tumors from U87 2ry and U87 parental cells. (D) 
Immunohistochemistry of SOX2 and SOX9 in these tumors. 
Figure 4. Downregulation of SOX2 in U251 cells. 
(A) Quantification of SOX2 and SOX9 protein levels in shSOX2 cells. Value is relative to 
pLKO transduced cells (n=5). (B) Cell growth of U251 cells at the indicated time points (n=4). 
(C, D) Representative images of P-H3 positive senescence associated β-galactosidase cells in 
shSOX2 and pLKO U251cells (n=4). (E) Data from cell cycle assay showing an arrest in G0/G1 
phase and a reduced S phase in shSOX2. (F) Representative image of 1ry GSC generated from 
control and shSOX2 cells. (G) Absolute number of spheres (1ry) formed from the indicated 
numbers of cells 
Figure 5. Effect of SOX9 restoration in shSOX2 cells 
(A,B) Image of P-H3 and senescence associated β-galactosidase positive cells in shSOX2 and 
shSOX2 restored with SOX9 in U251 cells. (C) shSOX2 and shSOX2+SOX9 transduced U251 
cells (2x103 cells) (n=4) were plated, and the number of colonies scored after two weeks. 
Figure 6. Downregulation of SOX9 in U251 cells.  
(A) SOX9 reduced A levels in shSOX9 (sh1) cells (n=3) compared to pRS control cells. (B) 
Representative inmunofluorescence of SOX9 in shSOX9 (sh1) cells. (C) Quantification of foci 
generated by sh1 and pRS cells in soft agar (n=4).  
Figure 7. Effect of SOX2 overexpression in glioma cell proliferation and self-renewal 
(A) Quantification of SOX2 and SOX9 protein in control and SOX2 overexpressed cells, 
corresponding to western blot of Figure 3E (n=4) (B,C) Representative image of P-H3 positive 
cells and spheres (1ry) in the indicated conditions of U87 cells  
Figure 8. SOX2 and SOX9 expression in glioma cells cultured with rapamycin, 
(A) Reduced SOX2 and SOX9 levels at increasing dosages of rapamycin (10nM and 100nM) in 
U373 cells (n=2). (B) Representative image of the action of rapamycin (1nM), TMZ (100µM) 
and both (1nM+100µM respectively) for 48 hours over SOX2 and SOX9 expression in U87MG 
and U251MG cells. Treatment with corresponding DMSO concentration was used as control 
treatment (n=3).  
Figure 9. Effect of cyclopamine in cells with variable SOX expression  
(A) Western blot of SOX2 and SOX9 in U251 glioma cells cultured for 48 h in the absence (-) 
or presence of 5µM of cyclopamine. (B) qRT-PCR of SOX2 and SOX9 mRNA levels in U251 
cells cultured with increasing concentrations of cyclopamine for 24 and 48 hours (n=3). (C) 
MTT assay of U87 and U251 glioma cell lines cultured with TMZ (100µM), increasing dosages 
of cyclopamine (5-10µM) and combination of both for 72h (n=5). 
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